The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.
1319 ET - Aquestive Therapeutics surges 44%, despite the FDA identifying deficiencies in the application for its Anaphylm Sublingual Film allergic reaction treatment. The company says the FDA's concerns were related to packaging and administration items that it should be able to address easily. "Basically we believe the FDA is comfortable with the efficacy and safety packages of this review, but really is being very careful here to make changes to avoid the product being used ineffectively in emergency situations," Cantor analysts Kristen Kluska and Richard Miller say. While the announcement likely removes most of the higher risk/worst case scenarios off the table, according to the analysts, they estimate the setback will lead to a 12 month delay in marketing. "But we do think there is a path forward in place to lead to an ultimate approval." (nicholas.miller@wsj.com)
1930 ET - ResMed's bull at Morgan Stanley reckons that the breath-tech provider's strong balance sheet can support continued share buybacks over its next six quarters. Analyst David L. Bailey tells clients in a note that he assumes a buyback of US$175 million in both of the third and fourth quarters, taking the fiscal 2026 total to US$675 million. He sees capacity for more to follow thanks to ResMed's strong cash flow generation, with US$175 million per quarter anticipated through fiscal 2027. He forecasts a net cash position of US$1.6 billion at the end of fiscal 2027, which suggests acquisitions are also an option. MS keeps a US$310.00 target price and overweight rating on ResMed's U.S.-listed stock, which last closed at US$258.31. (stuart.condie@wsj.com)
1831 ET - ResMed's bull at Macquarie stays positive on the breath-tech provider amid strong growth across all its revenue streams. ResMed's December-quarter revenue and profit were stronger than anticipated, while its gross margin was about 30 bps wider than Macquarie's forecast. A note from one of Macquarie's analysts flags revenue strength in masks, accessories and devices, adding that positive demand catalysts from weight-loss drugs and wearables support the stock's continued status as the investment bank's preferred sector exposure. Macquarie expects a full-year gross margin of 62.3%, compared with guidance of 62%-63%. Macquarie cuts its target price on ResMed's Australia-listed stock by 3.4% to A$47.50 and keeps an outperform rating. Shares are down 0.9% at A$37.20. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
February 02, 2026 16:50 ET (21:50 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
Comments